Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Irish Journal of Medical Science (1971 -)

03-05-2024 | Oral Cancer | Original Article

Short-term, nonsurgical periodontal therapy boosts interleukin-12 levels and reduces oral cancer risk

Authors: Hazza A. Alhobeira, Anamika Sharma, Ananya Sharma, Mahvish Khan, Mohtashim Lohani, Saif Khan, Eslam K. Fahmy, Safya E. Esmaeel, Anshoo Agarwal

Published in: Irish Journal of Medical Science (1971 -)

Login to get access

Abstract

Background

Cytokines, including interleukin-12 (IL-12), are proteins that regulate cell survival, proliferation, differentiation, and function. IL-12 is a heterodimeric proinflammatory cytokine. It possesses tumoricidal properties and promotes M1 macrophage polarization and IFN-γ production by T helper (Th1) cells, which in turn stimulates the antitumor cytotoxic cluster of eight positive (CD8+) and natural killer cells, therefore activating an effector immune response against tumor cells.

Materials and methods

Herein, the IL-2 levels of 60 patients with generalized chronic periodontitis (GCP) were assessed. Plaque index, gingival index, pocket probing depth, bleeding on probing percentage (BOP %), and clinical attachment loss were the clinical indicators reported.

Results

Patients with GCP in the pretreatment group had substantially lower mean IL-12 levels than those in the post-treatment group. Short-term, nonsurgical treatment (NST) considerably improved periodontal indices and increased IL-12 levels, thereby reducing oral cancer risk.

Conclusion

NST is a cost-effective and accessible cancer prevention procedure for general dentists.
Literature
1.
Shin YJ, Choung HW, Lee JH et al (2019) Association of periodontitis with oral cancer: a case-control study. J Dent Res 98(5):526–533PubMedCrossRef
2.
Kavarthapu A, Gurumoorthy K (2021) Linking chronic periodontitis and oral cancer: a review. Oral Oncol 121:105375PubMedCrossRef
3.
Sachdeva S, Saluja H, Mani A, Sonkar T (2020) Interleukins in periodontics. J Head Neck Physicians Surg 8(3):70
4.
Kaliński P, Hilkens CM, Snijders A et al (1997) IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 159(1):28–35PubMedCrossRef
5.
Del Vecchio M, Bajetta E, Canova S et al (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13(16):4677–4685PubMedCrossRef
6.
7.
Presky DH, Yang H, Minetti LJ et al (1996) A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 93(24):14002–14007PubMedPubMedCentralCrossRef
8.
Wang KS, Frank DA, Ritz J (2000) Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 95(10):3183–3190PubMedCrossRef
9.
Ye J, Huang Y, Que B et al (2018) Interleukin-12p35 knock out aggravates doxorubicin-induced cardiac injury and dysfunction by aggravating the inflammatory response, oxidative stress, apoptosis and autophagy in mice. E Bio Medicine 35:29–39
10.
Zwirner NW, Ziblat A (2017) Regulation of nk cell activation and effector functions by the IL-12 family of cytokines: the case of IL-27. Front Immunol 8:25PubMedPubMedCentralCrossRef
11.
Angiolillo AL, Sgadari C, Tosato G (1996) A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 795:158–167PubMedCrossRef
12.
13.
Kerkar SP, Goldszmid RS, Muranski P et al (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Investig 121(12):4746–4757PubMedPubMedCentralCrossRef
14.
Suzuki S, Umezu Y, Saijo Y et al (1998) Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Tohoku J Exp Med 185(3):223–226PubMedCrossRef
15.
Chiocca EA, Yu JS, Lukas RV et al (2019) Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Science Translational Medicine 11(505):eaaw5680PubMedPubMedCentralCrossRef
16.
Hewitt SL, Bailey D, Zielinski J et al (2020) Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment. Clin Cancer Res 26(23):6284–6298PubMedCrossRef
17.
Bekaii-Saab TS, Roda JM, Guenterberg KD et al (2009) A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with her2/neu-expressing malignancies. Mol Cancer Ther 8(11):2983–2991PubMedPubMedCentralCrossRef
18.
Díaz-Montero CM, El Naggar S, Al Khami A et al (2008) Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother 57(4):563–572PubMedCrossRef
19.
De la Rosa M, Zacarias GJ, Johnston DA, Radike AW (1979) Plaque growth and removal with daily toothbrushing. J Periodontol 50(12):661–664PubMedCrossRef
20.
Truyen E, Coteur L, Dilissen E et al (2006) Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax 61(3):202–208PubMedPubMedCentralCrossRef
21.
22.
Sharma A, Khattak BP, Naagtilak S et al (2014) Effect of periodontal therapy on salivary interleukin-12 levels in chronic periodontitis. J Clin Diagn Res 8(10):ZC90PubMedPubMedCentral
23.
Polson AM, Goodson JM (1985) Periodontal diagnosis. Current status and future needs. J Periodontol 56(1):25–34PubMedCrossRef
24.
Babitha GA, Nagpal D, Shripad SJ et al (2016) Interleukins in periodontal health and disease. Indian J Dent Adv 8(2):18–32
25.
Drisko CH (2001) Nonsurgical periodontal therapy. Periodontol 25(1):77–88CrossRef
26.
Söder B, Yakob M, Meurman JH et al (2012) The association of dental plaque with cancer mortality in Sweden. A longitudinal study. BMJ 2(3):e001083
27.
Moraes RC, Dias FL, Figueredo CM, Fischer RG (2016) Association between chronic periodontitis and oral/oropharyngeal cancer. Braz Dent J 27:261–266PubMedCrossRef
28.
Tibúrcio-Machado CS, Michelon C, Zanatta FB et al (2021) The global prevalence of apical periodontitis: a systematic review and meta-analysis. Int Endod J 54(5):712–735PubMedCrossRef
29.
Rylev M, Kilian M (2008) Prevalence and distribution of principal periodontal pathogens worldwide. J Clin Periodontol 35:346–361PubMedCrossRef
30.
Schenkein HA (1999) The pathogenesis of periodontal diseases. J Periodontol 70(4):457–470CrossRef
31.
32.
Löe H, Silness J (1963) Periodontal disease in pregnancy I. Prevalence and severity Acta Odontologica Scandinavica 21(6):533–551PubMedCrossRef
33.
Silness J, Löe H (1964) Periodontal disease in pregnancy II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 22(1):121–135PubMedCrossRef
34.
Johnson RB, Wood N, Serio FG (2004) Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol 75(1):37–43PubMedCrossRef
35.
Eke PI, Page RC, Wei L et al (2012) Update of the case definitions for population-based surveillance of periodontitis. J Periodontol 83(12):1449–1454PubMedPubMedCentralCrossRef
36.
37.
Chang H-D, Radbruch A (2007) The pro- and anti-inflammatory potential of interleukin-12. Ann N Y Acad Sci 1109:40–46PubMedCrossRef
38.
Claudino M, Garlet TP, Cardoso CRB et al (2010) Down-regulation of expression of osteoblast and osteocyte markers in periodontal tissues associated with the spontaneous alveolar bone loss of interleukin-10 knockout mice. Eur J Oral Sci 118(1):19–28PubMedCrossRef
39.
40.
Honda T, Domon H, Okui T et al (2006) Balance of inflammatory response in stable gingivitis and progressive periodontitis lesions. Clin Exp Immunol 144(1):35–40PubMedPubMedCentralCrossRef
41.
Okada H, Murakami S (1998) Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 9(3):248–266PubMedCrossRef
42.
Trinchieri G (1994) Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84(12):4008–4027PubMedCrossRef
43.
Sutterwala FS, Noel GJ, Clynes R, Mosser DM (1997) Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 185(11):1977–1985PubMedPubMedCentralCrossRef
44.
Ellis SD, Tucci MA, Serio FG, Johnson RB (1998) Factors for progression of periodontal diseases. J Oral Pathol Med 27(3):101–105PubMedCrossRef
45.
Fokkema SJ, Loos BG, De Slegte C, Burger W et al (2003) Increased release of IL-12p70 by monocytes after periodontal therapy. J Clin Periodontol 30(12):1091–1096PubMedCrossRef
46.
Orozco A, Gemmell E, Bickel M, Seymour GJ (2006) Interleukin-1β, interleukin-12 and interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis. Oral Microbiol Immunol 21(4):256–260PubMedCrossRef
47.
Seymour GJ, Gemmell E (2001) Cytokines in periodontal disease: where to from here? Acta Odontol Scand 59(3):167–173PubMedCrossRef
Metadata
Title
Short-term, nonsurgical periodontal therapy boosts interleukin-12 levels and reduces oral cancer risk
Authors
Hazza A. Alhobeira
Anamika Sharma
Ananya Sharma
Mahvish Khan
Mohtashim Lohani
Saif Khan
Eslam K. Fahmy
Safya E. Esmaeel
Anshoo Agarwal
Publication date
03-05-2024
Publisher
Springer International Publishing
Published in
Irish Journal of Medical Science (1971 -)
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-024-03695-5
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits